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In this report, we show that Epstein–Barr virus (EBV)-infected lymphoblastoid cell lines (LCL) express Fas and tumor
necrosis factor-related apoptosis-inducing ligand (TRAIL) receptor 2 and that LCL are lysed following engagement of these
receptors by agonist Fas and TRAIL receptor-specific monoclonal antibodies (MAb). We also show that EBV-specific CD41
T cells mediate bystander lysis of susceptible targets through both the Fas/Fas ligand (FasL) and the TRAIL pathways, but
find that the dominant mechanism of lysis following cognate, HLA class II-restricted recognition of LCL is the perforin/
granzyme pathway. Killing of LCL by EBV-specific CD41 T cells was strongly inhibited by concanamycin A, an agent that
elevates granule pH, resulting in accelerated destabilization and degradation of perforin. In contrast, blocking anti-FasL MAb
showed only limited inhibition of LCL killing. Blocking anti-TRAIL MAb had no effect on lysis of LCL by EBV-specific CD41 T
cells. We further show that culture of EBV-specific CD41 T cells in the presence of interleukin 4 markedly abrogates effector
cytotoxic function against LCL through direct depletion of intracellular perforin, with no evidence of a Th1 to Th2 shift in
patterns of cytokine expression. © 2001 Academic Press
Key Words: Epstein–Barr virus; CD41 T cell; Fas; TRAIL; perforin; interleukin-4.m
e
F
(INTRODUCTION
Epstein–Barr virus (EBV) is a B-lymphotropic herpes-
virus that is the causative agent of infectious mononu-
cleosis. Following primary infection, EBV persists as an
asymptomatic infection in 95–99% of adults worldwide.
The site of latent infection is the resting B cell (Miyashita
et al., 1997; Babcock et al., 1998). EBV is also closely
ssociated with the aggressive and rapidly lethal post-
ransplant B cell lymphoproliferative disorders (PTLD)
hat arise in immunosuppressed organ allograft recipi-
nts (Hanto et al., 1985; Nalesnik, 1996). There is a broad
onsensus that EBV-specific CD81 cytotoxic T cell re-
sponses play a central role in control of asymptomatic
infection in healthy adults, by virtue of their ability to lyse
proliferating B cells expressing viral antigens associated
with malignant transformation (Khanna et al., 1995; Rick-
inson et al., 1996). EBV-specific CD81 T cell responses
are inhibited in cyclosporin A-treated transplant patients
(Crawford et al., 1981; Gaston et al., 1982), who are
accordingly at high risk of developing PTLD. In addition
to the widely documented EBV-specific CD81 cytotoxic T
cell response, CD41 T cells capable of lysing EBV-trans-
1 To whom correspondence and reprint requests should be ad-
ressed at Department of Microbiology and Immunology, Mail Slot 511,
niversity of Arkansas for Medical Sciences, 4301 West Markham,
ittle Rock, AR 72205. Fax: (501) 686-5359. E-mail: cannonmartin@
ams.edu.79formed B lymphoblastoid cell lines (LCL) have also been
described (Misko et al., 1984; Rencher et al., 1994), but
otherwise little is known of EBV-specific CD41 T cell
function or their potential contribution to EBV-specific
immunosurveillance and control of PTLD.
Two major mechanisms account for most T-cell-medi-
ated cytotoxicity in vitro (Kagi et al., 1994). The first
pathway involves granule exocytosis and pore formation
in the target cell membrane through extracellular Ca21-
dependent polymerization of perforin, a lytic protein with
homology to the C9 component of the membrane attack
complex of complement. This is accompanied by release
of granzymes (serine proteases) responsible for down-
stream caspase activation and subsequent DNA frag-
mentation, resulting in target cell apoptosis. The per-
forin/granzyme pathway of cytotoxicity is the principal
modus operandi for CD81 T cells. The second pathway is
ediated by T cell Fas ligand (FasL) engagement of Fas
xpressed by target cells. Binding of Fas recruits the
as-associated death domain (FADD) and caspase-8
also known as FLICE, or FADD-like interleukin-1b-con-
verting enzyme), leading to the formation of the death-
inducing signaling complex (DISC). Formation of the
DISC results in activation of other downstream
caspases, notably caspase-3 and caspase-6, and the
death substrate poly(adenosine diphosphate)-ribose
polymerase, ultimately inducing efficient cell death (for
review, see Peter and Krammer, 1998). Utilization of the
Fas/FasL pathway of target cell lysis is thought to be0042-6822/01 $35.00
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80 KHANOLKAR, YAGITA, AND CANNONfavored by CD41 T cells (Shresta et al., 1998), and a
ecent report has indicated that EBV-specific CD41 T
cells can induce apoptosis in LCL via the Fas/FasL
pathway (Wilson et al., 1998). However, human virus-
specific CD41 T cells can also utilize the perforin/gran-
yme pathway of cytotoxicity (Gagnon et al., 1999; Ya-
ukawa et al., 1999).
Recent work has revealed that T cell induction of
target cell apoptosis may involve other receptor-medi-
ated pathways, the most notable of which is tumor ne-
crosis factor (TNF)-related apoptosis-inducing ligand
(TRAIL) (for review, see Griffith and Lynch, 1998). TRAIL
has attracted considerable attention by virtue of its pref-
erential ability to induce apoptosis in malignant or trans-
formed cells, but not in normal cells (Griffith and Lynch,
1998), and because of its potential as an anti-tumor
agent in vivo (Walczak et al., 1999). TRAIL is a type II
membrane protein of the TNF family that has the ability to
induce apoptosis in tumor cell lines (Wiley et al., 1995;
Pitti et al., 1996). TRAIL has significant homology with
other family members, notably FasL and TNFa. Four
membrane-bound TRAIL receptors have been identified
to date, of which TRAIL-R1 and -R2 are pro-apoptotic
receptors that possess death domains homologous to
those of Fas and TNF receptor-1. In contrast, TRAIL-R3
lacks a cytoplasmic domain and has a glycophospholipid
anchor in the cell membrane, and TRAIL-R4 has a trun-
cated cytoplasmic domain; neither of these receptors is
able to transmit a death signal. It has thus been sug-
gested that TRAIL-R3 and -R4 act as anti-apoptotic decoy
receptors for TRAIL and that target cell susceptibility to
TRAIL-induced apoptosis may be at least in part regu-
lated by differential expression of the four TRAIL recep-
tors. In practice, however, target cell susceptibility to
TRAIL-induced apoptosis cannot readily be correlated
with differential patterns of TRAIL receptor expression
(Griffith and Lynch, 1998), although expression of
TRAIL-R1 and/or TRAIL-R2 is a requirement.
To assess the contribution of CD41 T cells to immu-
osurveillance, and their potential for control of EBV-
riven PTLD, we have explored the mechanisms of EBV-
pecific cytotoxicity against in vitro transformed LCL. In
his report, we show that LCL express both Fas and
RAIL-R2 and are vulnerable to lysis following engage-
ent of Fas and TRAIL-R2. However, we find that EBV-
pecific CD41 T cells are strongly dependent on the
perforin/granzyme pathway for HLA class II-restricted
lysis of LCL and do not utilize FasL or TRAIL, although
they are capable of mediating non-HLA-restricted lysis of
bystander target cells by both these pathways. Finally,
we show that perforin-mediated lysis of LCL is abrogated
following culture of EBV-specific CD41 T cells in the
presence of interleukin-4 (IL-4). The reduction in lysis
was not a consequence of an IL-4-induced bias toward a
Th2 response, but was apparently due to a direct, cyto-
kine-induced depletion of intracellular perforin stores.RESULTS
Expression of Fas and TRAIL receptors by LCL
As CD41 T cells are considered to lyse target cells
rimarily through receptor–ligand induction of apoptosis,
e used flow cytometry to examine LCL for expression of
as and TRAIL receptors. All three LCL tested expressed
as at higher levels than Jurkat cells, which were used
s a positive control (not shown). K562 cells (a negative
ontrol) did not express Fas. LCL from donors 1 and 3
xpressed barely detectable levels of the pro-apoptotic
eceptor TRAIL-R1, whereas expression of TRAIL-R1 by
CL from donor 2 was not detected (Fig. 1). A second
ro-apoptotic receptor, TRAIL-R2, was expressed at sig-
ificant levels by LCL from donors 2 and 3, but only at
ery low levels by LCL from donor 1 (Fig. 1). Jurkat cells
xpressed TRAIL-R2 and a low level of TRAIL-R1. Expres-
ion of the anti-apoptotic decoy receptors TRAIL-R3 and
R4 by LCL or Jurkat cells was not detected (not shown).
ysis of LCL following engagement of TRAIL
eceptors and Fas
51Cr-labeled LCL were incubated in a 16-h cytotoxicity
ssay with varying levels of agonist anti-Fas monoclonal
ntibodies (MAb). All three LCL were susceptible to lysis
ollowing Fas engagement, as were Jurkat cells, which
re known to be sensitive to Fas-mediated apoptosis
Fig. 2). K562 cells, which do not express Fas, were not
ysed by the anti-Fas MAb. LCL were also sensitive to
ysis by plate-bound agonist MAb specific for TRAIL-R2
Fig. 3). In contrast, plate-bound agonist anti-TRAIL-R1
Ab induced minimal levels of LCL or Jurkat cell lysis
nd induced only a small increment in lysis when used in
ombination with anti-TRAIL-R2 (Fig. 3). The sensitivity of
CL to lysis following engagement of pro-apoptotic
RAIL receptors thus correlated with the observed pat-
erns of surface expression of TRAIL-R1 and TRAIL-R2
see Fig. 1).
xpression of FasL and TRAIL by EBV-specific CD41
T cells
Expression of FasL was tested by flow cytometry fol-
lowing CD41 T cell activation. FasL expression was not
detectable following antigen stimulation with LCL (not
shown), but all three CD41 T cell lines expressed FasL
following activation with anti-CD3 MAb (Figs. 4A–4F). In
contrast, we were unable to detect TRAIL expression by
flow cytometry, regardless of the activation state of the T
cells (not shown).
Lysis of LCL by EBV-specific CD41 T cells
To explore the mechanisms used by CD41 T cells for
lysis of target LCL, 16-h cytotoxicity assays were con-
ducted in the presence of blocking MAb specific for FasL
or TRAIL or in the presence of concanamycin A (CMA),
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81MECHANISMS OF EBV-SPECIFIC CD41 T CELL CYTOTOXICITYan agent that specifically inhibits the perforin/granzyme
pathway of target cell lysis (Kataoka et al., 1996). CMA,
an inhibitor of vacuolar H1 ATPase, promotes destabili-
ation and degradation of perforin through blockade of
ranule acidification. For all three CD41 T cell lines, we
found that CMA strongly inhibited LCL killing. In contrast,
anti-FasL MAb did not inhibit lysis by donor 1 CD41 T
cells, and the low level of inhibition of donor 2 and donor
3 CD41 T cells by anti-FasL MAb was not statistically
ignificant (Fig. 5). Anti-TRAIL MAb had no effect on the
1
FIG. 1. Expression of TRAIL receptors by donor 1 LCL (A and B),
donor 2 LCL (C and D), donor 3 LCL (E and F), and Jurkat cells (G and
H). Boldface profiles represent staining with MAb specific for TRAIL-R1
or TRAIL-R2 (as indicated), followed by secondary FITC-conjugated
goat anti-mouse IgG. Light profiles represent staining with an isotype
control MAb and FITC-conjugated goat anti-mouse IgG.ysis of LCL by CD4 T cells from donors 1 and 3, and theow level of inhibition of CD41 T cells from donor 2 was
ot statistically significant (Fig. 5B). These results show
hat the perforin/granzyme pathway is the dominant
echanism of LCL killing by EBV-specific CD41 T cells.
Are EBV-specific CD41 T cells capable of using the
FasL and TRAIL pathways of lysis?
Although we found that LCL could be lysed following
engagement of Fas or pro-apoptotic TRAIL-R1 and -R2,
CD41 T cells preferentially used the perforin/granzyme
pathway for lysis of LCL. These observations raised the
possibility that FasL and TRAIL were insufficiently ex-
pressed by the CD41 T cells following activation by LCL
see above) or that FasL and TRAIL were unable to
eliver an apoptotic signal. To test the ability of CD41 T
FIG. 2. Lysis of LCL following engagement of Fas. 51Cr-labeled LCL
ere incubated for 16 h with varying levels of the agonist CH11 anti-Fas
Ab. Target cells were donor 1 LCL (n ), donor 2 LCL (), donor 3 LCL
), Jurkat cells (F), and K562 cells (E). No cytotoxicity was observed
ollowing incubation with the same concentration of isotype control
ouse IgM antibody (not shown).
FIG. 3. Lysis of LCL following engagement of TRAIL-R1 and/or
TRAIL-R2. 96-well microtiter plates were coated with anti-TRAIL-R1 or
anti-TRAIL-R2 MAb, or both, or an isotype control MAb (all MAbs at 10
mg/ml in PBS, 50 ml/well overnight at 4°C). 51Cr-labeled donor 1 LCL
(n ), donor 2 LCL (), donor 3 LCL (}), or Jurkat cells (F) were added
to the washed plates in triplicate wells and incubated for 16 h.
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82 KHANOLKAR, YAGITA, AND CANNONcells to induce cell death via FasL or TRAIL, we con-
ducted bystander cytotoxicity assays against Jurkat cells,
a target that is susceptible to cell-mediated killing by
these mechanisms (Kayagaki et al., 1999). Because Jur-
kat cells do not express HLA class II molecules, and do
not induce alloresponsive CD41 T cell activation (data
not shown), cytotoxicity assays against this target were
carried out in the absence or in the presence of plate-
bound anti-CD3 MAb (to deliver a surrogate activation
signal).
Resting (i.e., nonactivated) CD41 T cells induced sig-
ificant lysis of Jurkat cells in a 16-h 51Cr-release assay
Fig. 6A). In contrast with the cytotoxicity assays against
CL, killing of Jurkat cells was not inhibited by CMA,
FIG. 4. EBV-specific CD41 T cell expression of FasL. A, B, and C
how expression of FasL by resting (i.e., nonactivated) CD41 T cells
rom donors 1, 2, and 3, respectively. D, E, and F show expression of
asL by CD41 T cells from donors 1, 2, and 3, respectively, 24 h after
ctivation by plate-bound anti-CD3 MAb (50 mg/ml OKT3, 50 ml/well
vernight at 4°C). Boldface profiles represent staining with NOK-2
nti-FasL MAb, and light profiles represent staining with an IgG2a
sotype control MAb.ndicating that the perforin/granzyme pathway was not a Somponent of bystander lysis. However, cytotoxicity was
trongly inhibited by blocking anti-TRAIL MAb and was
lightly inhibited by blocking anti-FasL MAb (Fig. 6A).
ysis of Jurkat cells was markedly enhanced following
D41 T cell activation by anti-CD3, but CMA again failed
to inhibit bystander lysis (Fig. 6B). In this instance, anti-
FasL MAb strongly inhibited killing, whereas anti-TRAIL
MAb had no inhibitory effect on lysis of Jurkat cells.
Essentially the same results were observed for all three
CD41 T cell lines. Collectively, these results indicate that
BV-specific CD41 T cells are capable of using both
FasL and TRAIL for target cell lysis and further suggest
that preferential utilization of these pathways may be
related to the activation status of the T cells.
FIG. 5. Mechanisms of LCL killing by EBV-specific CD41 T cells.
CD41 T cells and 51Cr-labeled donor 1 LCL (A), donor 2 LCL (B), or
donor 3 LCL (C) were incubated for 16 h at 37°C in triplicate wells at the
indicated effector:target ratios in the presence of CMA (), NOK-2
anti-FasL MAb (n ), or RIK-2 anti-TRAIL MAb (}), or in the absence of a
blocking agent (F). The concentration of CMA was 8 nM in all assays,
and NOK-2 MAb was used at 10 mg/ml in all assays. RIK-2 MAb was
used at 10 mg/ml in the assays against LCL from donors 1 and 3 and
at 20 mg/ml in the assay against LCL from donor 2. In each case,
MA-mediated inhibition of cytotoxicity was significant (P , 0.05,
tudent’s t test) at all effector:target ratios.
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83MECHANISMS OF EBV-SPECIFIC CD41 T CELL CYTOTOXICITYEBV-specific CD41 T-cell-mediated lysis of LCL is
nhibited by IL-4
Two independent studies have demonstrated elevated
evels of IL-4 in the serum of solid organ transplant
atients (Mathur et al., 1994; Martinez et al., 1995). The
resence of IL-4 may favor development of noncytotoxic
ype 2 (Th2) CD41 T cell responses at the expense of
ype 1 (Th1) responses with cytotoxic potential (Romag-
ani, 1991; Seder and Paul, 1994; Carter and Dutton,
996), thus raising the possibility that IL-4 may abrogate
BV-specific CD41 T cell cytotoxicity. To test this pro-
posal, we cultured CD41 T cells in the absence or in the
resence of recombinant human IL-4 (50 U/ml) and sub-
equently examined their ability to lyse LCL. A marked
eduction in killing was observed for the CD41 T cell line
erived from the heart transplant patient (donor 3) and
lso for a CD41 T cell line from one of the normal donors
(Fig. 7). Only short periods of IL-4 treatment (1–3 weeks)
were necessary to achieve this effect. However, the
reduction in cytotoxic function was not the result of an
FIG. 6. Bystander lysis of Jurkat cells by EBV-specific CD41 T cells
rom donor 1. Assays were conducted in the absence (A) or in the
resence (B) of plate-bound anti-CD3 MAb (50 mg/ml OKT3 in sterile
PBS, 50 ml/well, overnight at 4°C). CD41 T cells and 51Cr-labeled Jurkat
cells were added to the washed plates at the indicated effector:target
ratios in the presence of 8 nM CMA (), 10 mg/ml NOK-2 anti-FasL MAb
(n ), or 20 mg/ml RIK-2 anti-TRAIL MAb (}) or in the absence of a
locking agent (F). Assays were incubated for 16 h at 37°C. RIK-2
nti-TRAIL inhibition of Jurkat cell lysis by nonactivated CD41 T cells (A)
as significant (P , 0.05, Student’s t test) at all effector:target ratios.
OK-2 anti-FasL inhibition of Jurkat cell lysis by activated CD41 T cells
B) was significant (P , 0.05, Student’s t test) at all effector:target
atios.IL-4-induced Th2 bias, at least as revealed by analysis ofintracellular IFNg, IL-4, and IL-13 expression at the sin-
gle-cell level. When compared with matched, conven-
tional cultures, CD41 T cells grown in the presence of
IL-4 displayed an essentially unchanged pattern of intra-
cellular cytokine expression (Fig. 8).
IL-4 treatment of CD41 T cells results in depletion of
intracellular perforin stores
As IL-4-mediated inhibition of cytotoxicity was appar-
ently not a consequence of a Th2 bias in the CD41 T cell
response, we asked whether IL-4 had a direct effect on
cytotoxic function. As the perforin/granzyme pathway is
the major pathway for CD41 T cell lysis of LCL (see
bove), we looked at intracellular perforin levels in CD41
T cells cultured in the absence or in the presence of IL-4.
Flow cytometric analysis clearly showed that culture of
donor 3 CD41 T cells in the presence of IL-4 resulted in
a marked reduction of intracellular perforin expression
(Fig. 9).
DISCUSSION
In this report, we show that target LCL express Fas
and that LCL can be lysed following engagement of Fas
by agonist MAb. This observation supports and extends
earlier studies showing that proliferation of LCL was
FIG. 7. IL-4-induced modulation of CD41 T cell cytotoxicity against
CL. EBV-specific CD41 T cells from donor 1 (A) and CD41 T cells from
donor 3 (B) were cultured in the absence (F) or in the presence (E) of
50 U/ml recombinant human IL-4 for one or two passes (i.e., up to 3
weeks of culture). Cytotoxicity was tested against autologous LCL at
the indicated effector:target ratios in a 6-h 51Cr-release assay. For both
D41 T cells from donor 1 (A) and CD41 T cells from donor 3 (B),
IL-4-induced abrogation of cytotoxicity was significant (P , 0.05,
Student’s t test) at all effector:target ratios.
t
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84 KHANOLKAR, YAGITA, AND CANNONinhibited by anti-Fas (Falk et al., 1992). We also find that
LCL expressed TRAIL-R2 (and to a lesser extent TRAIL-
R1) and that LCL can be lysed following engagement of
these receptors by agonist MAb. In contrast, however,
we find that the dominant mechanism for HLA class
II-restricted lysis of LCL by EBV-specific CD41 T cells is
he perforin granzyme pathway, even though EBV-spe-
ific CD41 T cells are capable of utilizing both the Fas/
FIG. 8. Intracellular expression of IFNg, IL-4, and IL-13 by EBV-specif
(C and D) of 50 U/ml IL-4. T cells were activated with PMA and ionomyc
expression, as described under Materials and Methods. Control, i.e., n
FIG. 9. Intracellular perforin expression by EBV-specific CD41 T cell
cells from donor 3 were cultured with IL-4 for 19 days. Intracellular per
the cells.FasL and the TRAIL pathways for non-HLA-restricted
spontaneous or activation-dependent bystander lysis of
sensitive target cells.
One of the more intriguing findings was that EBV-
specific CD41 T cells were capable of lysing sensitive
bystander targets (Jurkat cells) via TRAIL without a re-
quirement for T cell activation. Furthermore, blocking
assays with Mab specific for TRAIL and FasL, respec-
T cells (donor 3) cultured in the absence (A and B) or in the presence
to permeabilization with saponin and staining for intracellular cytokine
ated, CD41 T cells failed to stain for cytokine expression (not shown).
red in the absence (A) or in the presence (B) of 50 U/ml IL-4. CD41 T
as measured by flow cytometry following saponin permeabilization ofic CD41
in prior
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85MECHANISMS OF EBV-SPECIFIC CD41 T CELL CYTOTOXICITYtively, showed that activation of CD41 T cells with plate-
bound anti-CD3 MAb abrogated TRAIL-mediated lysis of
Jurkat cells and favored lysis by the Fas/FasL pathway.
Utilization of the Fas/FasL pathway in bystander lysis by
activated CD41 T cells correlated with our observation
hat anti-CD3-mediated CD41 T cell activation resulted in
elevated expression of FasL. Although in this instance
we were unable to detect TRAIL expression by flow
cytometry, our finding that nonactivated CD41 T cells
preferentially utilize the TRAIL pathway for bystander
lysis is in accord with earlier observations that TRAIL is
constitutively expressed by human CD41 T cells and that
spontaneous cytotoxicity of resting human CD41 T cell
clones against sensitive targets can be blocked by anti-
TRAIL MAb, but not by anti-FasL MAb (Kayagaki et al.,
1999).
The observation that EBV-specific CD41 T cells show
a strong preference for utilization of the perforin/gran-
zyme pathway for HLA class II-restricted lysis of LCL
accords with other reports on the cytotoxic function of
human CD41 T cells (Lewinsohn et al., 1998; Rivoltini et
l., 1998; Gagnon et al., 1999; Yasukawa et al., 1999) and
ontrasts with the well-documented bias in favor of the
as/FasL pathway for mouse CD41 T cells (Shresta et al.,
1998). Collectively, our findings and those of other inves-
tigators suggest that the perforin/granzyme pathway may
be dominant for human CD41 T cells. The EBV-specific
CD41 T cell lines described in this study exhibited a
broad phenotypic range of cytokine expression, includ-
ing Th1 T cells expressing IFNg but not IL-4, Th2 T cells
xpressing IL-4 but not IFNg, and an intermediate phe-
notype expressing both IFNg and IL-4 (see Fig. 8). By
irtue of the polyclonal nature of these lines, perforin/
ranzyme-mediated cytolysis cannot readily be attrib-
ted to any particular CD41 T cell subset. Clonal analysis
of EBV-specific CD41 T cells may help to resolve this
uestion.
While there is no doubt that EBV-specific CD81 cyto-
toxic T cell responses play a crucial role in immunosur-
veillance, these results suggest that CD41 T cell re-
sponses may also be important. The preferential use of
the more potent perforin/granzyme pathway for lysis of
LCL strongly supports the proposal that EBV-specific
CD41 T cell responses against transformed B cells con-
ribute to immunosurveillance and maintenance of an
symptomatic carrier state in the healthy host. The use of
he perforin/granzyme pathway assumes further signifi-
ance in light of the finding that EBV-specific CD41 T
cells were ineffective in cytotoxicity assays against LCL
in which this pathway was inhibited by CMA, notwith-
standing the demonstration that LCL could be lysed
following engagement of Fas and TRAIL-R2 receptors
and that EBV-specific CD41 T cells were capable of
lysing sensitive bystander targets via the Fas/FasL and
TRAIL pathways. Our findings contrast with the observa-
tions of Wilson et al. (1998), who found that growth of LCL pcould be inhibited by EBV-specific CD41 T cells through
induction of Fas/FasL-mediated apoptosis, thus suggest-
ing a potential role for Fas/FasL interactions in CD41
T-cell-mediated immunosurveillance. The apparent dis-
crepancy between our results and those of Wilson et al.
ay be attributable to their use of phorbol myristyl ace-
ate (PMA)-activated LCL as stimulators for their CD41 T
ells. PMA treatment results in increased expression of
ytic cycle antigens and may also modify cytokine secre-
ion and expression of accessory and adhesion mole-
ules by LCL. All of these factors may influence the CD41
T cell response. In comparison with the EBV-specific
CD41 T cell responses we describe against conventional
LCL, CD41 T cells stimulated with PMA-treated LCL
showed very low cytotoxic responses against both PMA-
activated and untreated LCL (Wilson et al., 1998), sug-
gesting that PMA-activated LCL preferentially induce a
noncytotoxic response, at least as measured in a 5-h
51Cr-release assay.
Although we found that LCL were sensitive to lysis
ollowing engagement of Fas or TRAIL receptors by ag-
nist MAb, LCL were resistant to EBV-specific CD41 T
cell cytolysis in the presence of CMA, even in extended
16-h 51Cr-release assays. These results indicate that
D41 T cells are unable to compensate for the loss of
the perforin/granzyme pathway through utilization of the
Fas/FasL or TRAIL pathways, even though these mech-
anisms were found to be functional in bystander cytotox-
icity assays against sensitive Jurkat target cells. We also
found that anti-CD3-activated CD41 T cells (which ex-
press significant levels of FasL; see Fig. 4) do not lyse
LCL in extended 16-h 51Cr-release assays conducted in
the presence of CMA (not shown). It is thus apparent that
agonist MAb against Fas deliver a more potent apoptotic
signal than FasL-expressing EBV-specific CD41 T cells.
he relative resistance of LCL to CD41 T-cell-mediated
lysis via FasL or TRAIL may be due to overexpression of
FLICE-inhibitory protein, which has the capacity to inhibit
apoptosis following engagement of both Fas and TRAIL
receptors (French and Tschopp, 1999). Nevertheless, the
ability of MAb engagement of TRAIL-R2 to overcome the
resistance of LCL to receptor–ligand-induced apoptosis
suggests that recombinant soluble TRAIL may have ther-
apeutic potential for PTLD. Recombinant soluble TRAIL
has been effective in inhibiting tumor formation by hu-
man mammary adenocarcinoma cells in a SCID mouse
model and does not incur the hepatotoxicity associ-
ated with recombinant soluble FasL or TNFa treatment
(Walczak et al., 1999).
Perhaps the most remarkable observation from this
study is the finding that culture of EBV-specific CD41 T
ells in the presence of IL-4 resulted in a marked abro-
ation of cytotoxicity against LCL. IL-4-induced inhibition
f CD41 T cell cytotoxic function did not correlate with a
hange in pattern of cytokine expression, but was ap-
arently due to depletion of intracellular perforin stores.
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86 KHANOLKAR, YAGITA, AND CANNONThis finding is of particular interest in light of reports
describing elevated serum IL-4 levels in immunosup-
pressed solid organ allograft recipients (Mathur et al.,
1994; Martinez et al., 1995). Collectively, these observa-
tions suggest that IL-4 may play a direct role in abroga-
tion of EBV-specific T cell immunosurveillance in high-
risk individuals under cyclosporin A (CsA) therapy. It
should also be noted that CsA can inhibit FasL expres-
sion (Nakajima and Oka, 1996), thus short-circuiting a
potential alternative pathway of lysis in vivo.
MATERIALS AND METHODS
Stimulator/target cells
EBV-transformed LCL were established by infection of
peripheral blood lymphocytes (PBL) with the B95.8 strain
of EBV in the presence of 1 mg/ml CsA and maintained in
PMI 1640 supplemented with 10% fetal calf serum
FCS), 3 mM glutamine, 100 IU/ml penicillin, 100 mg/ml
treptomycin, and 5 3 1025 M 2-mercaptoethanol (RPMI/
10), as described (Nazaruk et al., 1998), except that in
ome cases the medium was supplemented with 10%
uman AB (HuAB) serum (Gemini Bio-Products, Calaba-
as, CA) (RPMI/10Hu) rather than 10% FCS. Jurkat cells
nd K562 cells were maintained in RPMI/10.
BV-specific CD41 T cell lines
CD41 T cell lines (and matching LCL; see above) were
erived from two healthy adult individuals (donors 1 and
) and one heart transplant patient (donor 3), who was
nder CsA immunosuppressive therapy (100 mg, oral,
wice daily). The blood level of CsA at the time of blood
rawing was 167 ng/ml. CD41 T cells were purified from
PBL by positive selection with anti-CD4-coupled Dyna-
beads (Dynal A.S., Lake Success, NY). A total of 3 3 107
PBL were incubated with 2 3 107 anti-CD4-Dynabeads in
ml PBS/2% HuAB serum at 4°C for 1 h. Dynabead-
osetted CD41 T cells were magnetically separated,
washed five times with cold PBS/2% HuAB serum, and
subsequently recovered by incubation with 60 ml CD4-
Detachabead reagent (Dynal A.S.) in 150 ml RPMI/10Hu.
Purified CD41 T cells (3 3 105/ml) were cocultured with
autologous, irradiated (7500 cGy) LCL (2 3 105/ml) in
RPMI/10Hu for 9–11 days, after which period the T cells
were restimulated with irradiated LCL. Recombinant hu-
man IL-2 (50 U/ml; provided by the Biological Response
Modifiers Program, National Cancer Institute, Bethesda,
MD) was added to the cultures at this time. EBV-specific
CD41 T cells were subsequently maintained by restimu-
lation with irradiated LCL every 14–21 days, with interim
50–70% changes of fresh medium plus IL-2 every 2 to 4
days. LCL used for CD41 T cell stimulation were main-
tained in RPMI/Hu, to avoid stimulation of CD41 T cells
specific for bovine serum protein. The purity of the CD41T cells was continuously monitored by flow cytometric ianalysis. In all experiments, CD41 T cells were 98–100%
pure, with no detectable contamination by CD81 T cells.
Definition of CD41 T cell specificity for EBV
The specificity of the CD41 T cell lines was confirmed
in proliferation assays against LCL and EBV-uninfected
normal, activated By lymphoblasts. Briefly, CD41 T cells
proliferated strongly in response to stimulation with au-
tologous LCL maintained in medium supplemented with
FCS or HuAb serum, but failed to recognize HLA class
II-mismatched allogeneic LCL. In addition, responses
against autologous LCL could be markedly inhibited (50–
80% reduction in stimulation indices) in the presence of
blocking anti-HLA class II MAb.
Most important, CD41 T cells failed to mount prolifer-
ative or cytotoxic responses against autologous, normal
(i.e., non-EBV-transformed) B lymphoblasts activated with
anti-CD40 MAb and IL-4 in the presence of CDw32-
transfected L cells (Banchereau et al., 1991), as previ-
ously reported (Fu and Cannon, 2000). CDw32 encodes
an IgG Fc receptor, which cross-links the anti-CD40
MAb, thereby delivering an activation signal to the B
cells. Flow cytometric analysis indicated that the normal
B lymphoblasts were phenotypically comparable to LCL.
Like LCL, normal B lymphoblasts expressed high levels
of CD23 and adhesion molecules CD54 (ICAM-1) and
CD58 (LFA-3). Finally, the anti-CD40-activated B lympho-
blasts expressed high levels of CD86 and HLA-DR, indi-
cating that they would be excellent antigen-presenting
cells (as are LCL, which also express CD86 and HLA-
DR). Collectively, this analysis shows that the normal B
lymphoblasts are fully activated and phenotypically com-
parable to LCL.
Flow cytometry
FITC-conjugated anti-Fas MAb were from Becton-
Dickinson (San Jose, CA). For detection of FasL expres-
sion, we used NOK-2 MAb (Kayagaki et al., 1995). TRAIL
expression was detected with RIK-2 MAb (Kayagaki et
l., 1999) or M180 MAb (Immunex Corp., Seattle, WA).
Ab specific for TRAIL receptors were also kindly pro-
ided by Immunex Corp. FITC-conjugated goat anti-
ouse IgG was from Sigma (St. Louis, MO). For staining
f surface markers, cells were washed once in phos-
hate-buffered saline (PBS) and incubated with primary
ntibody for 30 min on ice, after which they were washed
wice with cold PBS. Where unconjugated primary anti-
odies were used, the cells were incubated for a further
0 min on ice with FITC-conjugated secondary antibod-
es. After two further washes with PBS, the cells were
ixed with 2% paraformaldehyde in PBS. FITC-conjugated
nti-perforin MAb and a FITC-conjugated isotype control
ere from PharMingen (San Diego, CA). For intracellular
taining of perforin, cells were washed and permeabil-
zed by incubation in PBS plus 1% bovine serum albumin
t
s
c
o
i
m
w
6
t
w
c
f
a
m
s
F
g
t
t
B
B
i
F
F
F
G
M
M
M
87MECHANISMS OF EBV-SPECIFIC CD41 T CELL CYTOTOXICITY(BSA) and 0.5% saponin (S-7900; Sigma) for 10 min at
room temperature. After being stained for 30 min at room
temperature, cells were washed twice with PBS plus 1%
BSA and 0.5% saponin, washed once with PBS plus 0.5%
BSA, and fixed with 2% paraformaldehyde in PBS. Flow
cytometric analysis was conducted with a FACScan
(Becton-Dickinson), using LYSIS II software (Becton-
Dickinson) and WinMDI 2.7 software (kindly made avail-
able by Joe Trotter, The Scripps Research Institute, La
Jolla, CA).
Cytotoxicity assays
Cytotoxicity against LCL and Jurkat cells was tested in
standard 6- or 16-h 51Cr-release assays in 96-well micro-
iter plates at indicated effector:target ratios, as de-
cribed (Nazaruk et al., 1998). The role of perforin in
ell-mediated cytotoxicity was assessed by the addition
f 8 nM CMA (Sigma). The NOK-2 anti-FasL MAb (10
mg/ml) was used to inhibit Fas/FasL-mediated lysis, and
the RIK-2 anti-TRAIL MAb (10–20 mg/ml) was used to
nhibit TRAIL-mediated cytotoxicity. Where appropriate,
icrowells were precoated with anti-CD3 MAb (50 mg/ml
OKT3 in PBS, 50 ml/well overnight at 4°C).
Intracellular cytokine expression
T cells were rested for at least 14 days following
antigen stimulation before activation with PMA and iono-
mycin, as described (Nazaruk et al., 1998; Fu and Can-
non, 2000). Briefly, T cells (7.5 3 105/ml) were incubated
ith 50 ng/ml PMA and 500 ng/ml ionomycin at 37°C for
h in RPMI/10Hu. Brefeldin A (10 mg/ml) was added for
he final 3 h of incubation. Control, nonactivated cultures
ere incubated with the addition of Brefeldin A only. The
ells were harvested, washed, and fixed with 2% para-
ormaldehyde in PBS for 20 min at room temperature,
fter which they were washed once with PBS and per-
eabilized by incubation in PBS plus 1% BSA and 0.5%
aponin for 10 min at room temperature. MAb used were
ITC-conjugated anti-IFNg and phycoerythrin (PE)-conju-
ated anti-IL-4 and anti-IL-13, respectively (all from Bec-
on-Dickinson). After being stained for 30 min at room
emperature, cells were washed twice with PBS plus 1%
SA and 0.5% saponin, washed once with PBS plus 0.5%
SA, and fixed a second time with 2% paraformaldehyde
n PBS prior to flow cytometric analysis.
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